Lantern Pharma (LTRN) Assets (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Assets came in at $7.2 million in Q1 2026, down 65.76% YoY from $21.1 million in Q1 2025, and down 34.55% on a QoQ basis from $11.0 million in Q4 2025.
Lantern Pharma (LTRN) Assets (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Assets data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Assets fell 65.76% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 65.76% YoY) and the FY2025 annual result came in at $11.0 million, down 56.84% from the prior year.
- Assets slipped to $7.2 million in Q1 2026, from $11.0 million in the prior quarter.
- In the past five years, Assets ranged from a high of $68.4 million in Q1 2022 to a low of $7.2 million in Q1 2026.
- A 5-year average of $38.6 million and a median of $39.7 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets retreated 17.09% — and 2026, when it slumped 65.76%.
- Tracing LTRN's Assets over 5 years: stood at $58.8 million in 2022, then declined by 25.82% to $43.6 million in 2023, then tumbled by 41.41% to $25.6 million in 2024, then sank by 56.84% to $11.0 million in 2025, then slumped by 34.55% to $7.2 million in 2026.
- The last three Assets figures came in at $7.2 million (Q1 2026), $11.0 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.22 Mn |
| Dec 31, 2025 | 11.04 Mn |
| Sep 30, 2025 | 13.63 Mn |
| Jun 30, 2025 | 17.42 Mn |
| Mar 31, 2025 | 21.10 Mn |
| Dec 31, 2024 | 25.57 Mn |
| Sep 30, 2024 | 30.29 Mn |
| Jun 30, 2024 | 35.59 Mn |
| Mar 31, 2024 | 39.73 Mn |
| Dec 31, 2023 | 43.65 Mn |
| Sep 30, 2023 | 47.77 Mn |
| Jun 30, 2023 | 51.43 Mn |
| Mar 31, 2023 | 55.51 Mn |
| Dec 31, 2022 | 58.84 Mn |
| Sep 30, 2022 | 62.16 Mn |
| Jun 30, 2022 | 66.38 Mn |
| Mar 31, 2022 | 68.40 Mn |
| Dec 31, 2021 | 73.95 Mn |
| Sep 30, 2021 | 77.61 Mn |
| Jun 30, 2021 | 82.43 Mn |